Overview

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Status:
Completed
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Collaborators:
Amgen
Onyx Pharmaceuticals
Treatments:
Niacinamide
Sorafenib